Interim Report, January – September 2006
KEY EVENTS DURING THE PERIOD
-Net sales amounted to MSEK 80.3 (59.0)
-The loss after tax was MSEK 20.5 (loss: 7.9)
-Earnings per share amounted to a loss of SEK 1.54 (loss: 0.84)
-Orexo's European partner, ProStrakan, submitted a registration application for Rapinyl™ to the EMEA registration authority.
-Orexo received a milestone payment of MEUR 2 in conjunction with ProStrakan’s submission of a registration application for Rapinyl™ to the EMEA.
THIRD QUARTER 2006
-Net sales amounted to MSEK 24.9 (56.1)
-The loss after tax was MSEK 11.2 (profit: 27,4)
-Earnings per share amounted to a loss of SEK 0.84 (profit: 2.89)
For Interim report in full format, see enclosed pdf.
For more information, please contact:
Zsolt Lavotha, President & CEO, Tel: +46 (0)18-780 88 12, e-mail: firstname.lastname@example.org
Claes Wenthzel, Executive Vice President and CFO, Tel: +46 (0)18-780 88 44, e-mail: email@example.com